Scribe’s cardiometabolic programs gain CIRM boost
BioWorld
|
June 19, 2026
X min read
BioWorld
|
June 19, 2026
Share on Social
More like this
Media
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Press
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
July 27, 2026
Read Now
Media
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
July 23, 2026
Read Now
Press
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
July 23, 2026
Read Now
Media
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
Press
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
